The present investigation deals with improving solubility and dissolution rate, thereby achieving greater bioavailability and absorption by the Liquisolid Compact Technique. The significant therapeutic efficacy of Azelnidipine for the therapy of hypertension was attained. Liquisolid compact is the most effective technique based on the incorporation of suitable non-volatile liquid for the improvement of solubility. The liquid medicament is transformed into a free-flowing compacted material by adding a carrier and coating agent. The compatibility was confirmed with FTIR and thermal analysis with DSC. PEG 400 was chosen to indicate the highest solubility. The optimization was performed with Box-Behnken design using Design of Expert software considering the extent of carrier, coating, and superdisintegrant as independent factors and disintegration, dissolution was the dependent factor. The Box-Behnken design was implemented which predicted 12 runs and ANOVA with p-values was 0.0285 and 0.0444 for dependable parameters such as disintegration time and dissolution respectively. The Response surface methodology was retrieved with the 2-D Contour and 3-D plots along with ANOVA. The F2 was an optimized batch with an excellent flowability index and disintegration time of 3.01 min. The medicaments within 30 minutes with a higher dissolution rate of 99.38 %. The F2 batch qualified for stability testing when retained at 40 0 C and 75 % RH. The superior improvement in solubility and dissolution level of AZN was achieved with the Liquisolid Compaq technique.